C-Max: Maximizing the Cancer Fighting Power of Vitamin C
Cancer is more prevalent than ever, and the therapies prescribed to address it range from herbs to radiation and everything in between.
In spite of its lack of promotion, vitamin C has occupied a central role among natural cancer therapies. It’s potent, safe, and even addresses other therapeutic concerns and supports general health at the same time.
What is more, science has found that when synergistic nutrients are added to vitamin C, its ability to address cancer is significantly improved. And this is what brings us to what is known as CK3 therapy, and by extension, C-Max.
CK3 (vitamin C and vitamin K3) therapy was introduced in 2003 by Verrax, Delveaux, Jamison and others as a “new, non-toxic adjuvant cancer therapy.” https://www.sciencedirect.com/science/article/abs/pii/S0223523403000825?via%3Dihub. The authors noted that CK3 causes a “new” type of cancer cell death called autoschizis.
Subsequent studies of CK3 therapy found that cancer cell death is accentuated when CK3 therapy is administered at a ratio of 1000:1 (C:K3). Bonilla-Porras, Jimenez-Del Rio and Valez-Pardo (2011) found that “[cancer] cell death was more prominent when [Jurkat and K562] cells are exposed to VC and VK3 in a ratio 1000:1 (10 mM: 10 μM) or 100:1 (300 μM: 3 μM), respectively.” https://cancerci.biomedcentral.com/articles/10.1186/1475-2867-11-19.
C-Max utilizes this same ratio, but instead of utilizing intravenous delivery, it utilizes natural phospholipid liposomes that can be taken orally.
Research into CK3 has continued into the present. Below are a variety of links to recent studies of the chemotherapeutic efficacy of the combination of vitamins C and K3. Some of these analyze CK3 as a standalone therapy; others for its synergistic effect with pharmaceutical approaches.
2020: CK3 kills cancer cells, leaving healthy cells intact: https://pubmed.ncbi.nlm.nih.gov/32234885/
2020: Selective Targeting of Cancerous Mitochondria and Suppression of Tumor Growth Using Redox-Active Treatment Adjuvant: https://pubmed.ncbi.nlm.nih.gov/33204397/
2020: Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib: https://pubmed.ncbi.nlm.nih.gov/29491065/
2020: Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells: https://pubmed.ncbi.nlm.nih.gov/32316111/
2020: Improved redox anti-cancer treatment efficacy through reactive species rhythm manipulation: https://pubmed.ncbi.nlm.nih.gov/32005913/
2019: The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress: https://pubmed.ncbi.nlm.nih.gov/30703479/
2015: CK3 efficacy in Ovarian cancer: https://www.sciencedirect.com/science/article/pii/S2214854X15300066
2008: Targeting cancer cells by an oxidant-based therapy: https://pubmed.ncbi.nlm.nih.gov/20021426/
As the research continues, so will IVtoGo continue to push the boundaries of portable, high-dose vitamin therapy. Thanks for reading!